Pharvaris (PHVS) Competitors $23.28 -0.22 (-0.94%) As of 11:46 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock PHVS vs. PTCT, KRYS, PCVX, ACAD, ACLX, ADMA, ARWR, MENS, MIRM, and MLTXShould you be buying Pharvaris stock or one of its competitors? The main competitors of Pharvaris include PTC Therapeutics (PTCT), Krystal Biotech (KRYS), Vaxcyte (PCVX), ACADIA Pharmaceuticals (ACAD), Arcellx (ACLX), ADMA Biologics (ADMA), Arrowhead Pharmaceuticals (ARWR), Jyong Biotech (MENS), Mirum Pharmaceuticals (MIRM), and MoonLake Immunotherapeutics (MLTX). These companies are all part of the "pharmaceutical products" industry. Pharvaris vs. Its Competitors PTC Therapeutics Krystal Biotech Vaxcyte ACADIA Pharmaceuticals Arcellx ADMA Biologics Arrowhead Pharmaceuticals Jyong Biotech Mirum Pharmaceuticals MoonLake Immunotherapeutics PTC Therapeutics (NASDAQ:PTCT) and Pharvaris (NASDAQ:PHVS) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, risk, profitability, analyst recommendations, valuation, earnings and dividends. Which has higher earnings and valuation, PTCT or PHVS? Pharvaris has lower revenue, but higher earnings than PTC Therapeutics. Pharvaris is trading at a lower price-to-earnings ratio than PTC Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPTC Therapeutics$806.78M5.97-$363.30M$6.978.70PharvarisN/AN/A-$145.24M-$3.36-6.93 Do analysts recommend PTCT or PHVS? PTC Therapeutics presently has a consensus target price of $69.00, indicating a potential upside of 13.75%. Pharvaris has a consensus target price of $34.00, indicating a potential upside of 46.05%. Given Pharvaris' stronger consensus rating and higher probable upside, analysts plainly believe Pharvaris is more favorable than PTC Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PTC Therapeutics 1 Sell rating(s) 5 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.53Pharvaris 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80 Is PTCT or PHVS more profitable? PTC Therapeutics has a net margin of 35.65% compared to Pharvaris' net margin of 0.00%. Pharvaris' return on equity of -69.09% beat PTC Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets PTC Therapeutics35.65% -106.31% 30.61% Pharvaris N/A -69.09%-63.34% Does the media refer more to PTCT or PHVS? In the previous week, PTC Therapeutics had 14 more articles in the media than Pharvaris. MarketBeat recorded 17 mentions for PTC Therapeutics and 3 mentions for Pharvaris. Pharvaris' average media sentiment score of 1.10 beat PTC Therapeutics' score of 0.92 indicating that Pharvaris is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PTC Therapeutics 9 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Pharvaris 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk & volatility, PTCT or PHVS? PTC Therapeutics has a beta of 0.53, indicating that its share price is 47% less volatile than the S&P 500. Comparatively, Pharvaris has a beta of -2.8, indicating that its share price is 380% less volatile than the S&P 500. SummaryPTC Therapeutics beats Pharvaris on 8 of the 13 factors compared between the two stocks. Get Pharvaris News Delivered to You Automatically Sign up to receive the latest news and ratings for PHVS and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PHVS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PHVS vs. The Competition Export to ExcelMetricPharvarisMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.22B$3.18B$5.80B$10.16BDividend YieldN/A2.32%5.69%4.61%P/E Ratio-6.9321.4874.7325.99Price / SalesN/A301.34470.3491.76Price / CashN/A45.3337.0859.91Price / Book4.209.6312.256.31Net Income-$145.24M-$53.32M$3.28B$270.66M7 Day Performance1.00%0.95%1.39%3.52%1 Month Performance10.38%9.68%7.70%6.79%1 Year Performance13.45%13.38%64.01%28.29% Pharvaris Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PHVSPharvaris2.5461 of 5 stars$23.28-0.9%$34.00+46.0%+12.0%$1.22BN/A-6.9330Positive NewsPTCTPTC Therapeutics3.6468 of 5 stars$56.95-0.5%$69.00+21.2%+88.9%$4.55B$806.78M8.171,410Insider TradeKRYSKrystal Biotech4.942 of 5 stars$145.20-3.4%$210.38+44.9%-27.4%$4.35B$290.52M29.51210Positive NewsPCVXVaxcyte2.2918 of 5 stars$32.41-1.8%$130.00+301.1%-70.9%$4.29BN/A-7.89160Positive NewsAnalyst ForecastACADACADIA Pharmaceuticals4.3958 of 5 stars$25.39+0.5%$28.88+13.7%+51.7%$4.26B$957.80M19.09510Positive NewsAnalyst ForecastACLXArcellx2.2443 of 5 stars$71.11-2.1%$114.31+60.7%+4.4%$4.03B$107.94M-20.7980Positive NewsADMAADMA Biologics3.7357 of 5 stars$16.42-2.7%$27.67+68.5%-4.7%$4.03B$426.45M19.09530Positive NewsARWRArrowhead Pharmaceuticals4.1574 of 5 stars$27.17-6.6%$43.14+58.8%+41.9%$4.02B$3.55M-21.23400Analyst RevisionMENSJyong BiotechN/A$55.68+6.4%N/AN/A$3.98BN/A0.0031News CoverageGap DownHigh Trading VolumeMIRMMirum Pharmaceuticals3.2009 of 5 stars$77.39+1.7%$74.13-4.2%+81.3%$3.82B$336.89M-63.96140Analyst ForecastMLTXMoonLake Immunotherapeutics2.5283 of 5 stars$61.12+2.8%$74.43+21.8%+17.0%$3.82BN/A-21.992Positive News Related Companies and Tools Related Companies PTC Therapeutics Alternatives Krystal Biotech Alternatives Vaxcyte Alternatives ACADIA Pharmaceuticals Alternatives Arcellx Alternatives ADMA Biologics Alternatives Arrowhead Pharmaceuticals Alternatives Jyong Biotech Alternatives Mirum Pharmaceuticals Alternatives MoonLake Immunotherapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PHVS) was last updated on 9/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredAlert: Prepare for Trump's Dollar OverhaulPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredNVDA: The cracks are beginning to showThe media hasn't caught up to the story yet, but when they do, this stock could leave Nvidia in the dust. I...InvestorPlace | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredUrgent: $3,452.50 a Month in Passive "AI Equity Checks"The U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredCollege grad makes $64,000 a monthA Wall Street legend just helped train our own proprietary AI system in the stock market (a project that took ...Stansberry Research | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pharvaris N.V. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pharvaris With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PHVS Stock Alerts